Abstract CT106: Efficacy of pertuzumab/trastuzumab/paclitaxel over standard trastuzumab/paclitaxel therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Year: 2016
Type: conference-abstract
Source: Cancer Research
Authors: Meredith Buxton, Angela M. DeMichele, Stephen Chia, Laura van't Veer, Jo Chien, Anne Wallace, Henry Kaplan, Julie Lang, Douglas Yee, Claudine Isaacs, Stacy Moulder, Kathy Albain, Judy Boughey, Kathleen Kemmer, Barbara Haley, Susan Minton, Andres Forero, Rita Nanda, Anthony Elias, Larissa Korde, Rebecca Viscuzi, Hope Rugo, Richard Schwab, Fraser Symmans, Melissa Paoloni, Nola Hylton, Michael Hogarth, Julia Lyandres, Jane Perlmutter, Ashish Sanil, Christina Yau, Laura Esserman, Don Berry, I-SPY 2 TRIAL Investigators
Institutions: University of California, San Francisco, University of Pennsylvania, University of California San Diego, Swedish Medical Center, University of Southern California, University of Minnesota, Georgetown University, The University of Texas MD Anderson Cancer Center, Loyola University Medical Center, Loyola Medicine, Mayo Clinic, Oregon Health & Science University, The University of Texas Southwestern Medical Center, Moffitt Cancer Center, University of Alabama at Birmingham, University of Chicago, University of Colorado Denver, University of Washington, University of Arizona, University of Arizona Cancer Center, University of California, Davis, Patient-Centered Outcomes Research Institute, Berry Consultants, LLC (United States)
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2480350079